scholarly journals Impact of preimplantation genetic testing for aneuploidy (PGT-A) on gestational carrier (GC) cycles in the United States

2019 ◽  
Vol 112 (3) ◽  
pp. e227
Author(s):  
Reeva B. Makhijani ◽  
Madeline Coulter ◽  
Jeffrey Thorne ◽  
Chantal Bartels ◽  
John Nulsen ◽  
...  
Keyword(s):  
United States ◽  
Genetic Testing ◽  
The United States ◽  
Preimplantation Genetic Testing ◽  
Gestational Carrier

STATE INSURANCE MANDATES AND TRENDS IN PREIMPLANTATION GENETIC TESTING (PGT) UTILIZATION IN THE UNITED STATES

2020 ◽  
Vol 114 (3) ◽  
pp. e109
Author(s):  
Bronwyn S. Bedrick ◽  
Andrew D. Tipping ◽  
Katelin B. Nickel ◽  
Joan Riley ◽  
Tarun Jain ◽  
...  
Keyword(s):  
United States ◽  
Genetic Testing ◽  
The United States ◽  
Preimplantation Genetic Testing ◽  
Insurance Mandates

scholarly journals STATE-MANDATED INSURANCE AND PREIMPLANTATION GENETIC TESTING (PGT) INDICATION IN THE UNITED STATES

2020 ◽  
Vol 114 (3) ◽  
pp. e13-e14
Author(s):  
Bronwyn S. Bedrick ◽  
Andrew D. Tipping ◽  
Katelin B. Nickel ◽  
Joan Riley ◽  
Tarun Jain ◽  
...  
Keyword(s):  
United States ◽  
Genetic Testing ◽  
The United States ◽  
Preimplantation Genetic Testing

BRCA1/2 Genetic Testing in the Community Setting

2002 ◽  
Vol 20 (22) ◽  
pp. 4485-4492 ◽  
Author(s):  
Wendy Y. Chen ◽  
Judy E. Garber ◽  
Suzanne Higham ◽  
Katherine A. Schneider ◽  
Katie B. Davis ◽  
...  
Keyword(s):  
United States ◽  
Ovarian Cancer ◽  
Genetic Testing ◽  
Cancer Prevention ◽  
Community Setting ◽  
The United States ◽  
Care Providers ◽  
Prevention Strategies ◽  
History Of ◽  
Genetic Results

PURPOSE: BRCA1/2 genetic testing has been commercially available in the United States since 1996. Most published reports described BRCA1/2 testing as research studies at large academic centers, but less is known about testing in the community. This study evaluates the process and early outcomes of BRCA1/2 genetic testing as a clinical service in the community setting. METHODS: Surveys were mailed to women in the United States whose health care providers ordered BRCA1/2 genetic testing from Myriad Genetic Laboratories from August 1998 through July 2000. Women tested at 149 large academic centers were excluded. Main outcome measures were demographic characteristics, recall of and satisfaction with the genetic testing process, and likelihood of pursuing cancer prevention strategies. RESULTS: Among the 646 respondents, 414 (64%) had a personal history of cancer and 505 (78%) had at least one first-degree relative with breast and/or ovarian cancer. Most subjects (82%) recalled discussions of informed consent before testing (median time, 30 minutes). Genetic results were conveyed during an office visit (57%), by telephone (39%), or by mail (3%). More than 75% of respondents were “very satisfied with the counseling received.” Cancer-free subjects with a germline mutation were more likely to consider prevention strategies after receiving the genetic results. CONCLUSION: Virtually all respondents had a personal and/or family history of breast/ovarian cancer. Although pretest and posttest communications were not standardized, overall satisfaction with clinical breast cancer genetic testing was high. Additional follow-up will provide data on future cancer prevention practices and cancer incidence.

scholarly journals Genetic Testing by Sports Medicine Physicians in the United States: Attitudes, Experiences, and Knowledge

Sports ◽  
2018 ◽  
Vol 6 (4) ◽  
pp. 145
Author(s):  
Eleanor Taranto ◽  
Michael Fishman ◽  
Holly Benjamin ◽  
Lainie Ross
Keyword(s):  
United States ◽  
Genetic Testing ◽  
Sports Medicine ◽  
Injury Risk ◽  
Expert Knowledge ◽  
Disease Risk ◽  
Sickle Cell Trait ◽  
Positive Family History ◽  
The United States ◽  
Medical Society

It remains unknown whether and how sports medicine physicians currently utilize genetic testing in their clinical practice. This study sought to assess knowledge of, experience with, and attitudes towards genetic testing by sports medicine physicians in the United States (US). An email with a survey hyperlink was distributed twice to members of the American Medical Society for Sports Medicine (AMSSM) listserv in September 2016, with approximately a 10% response rate. Questions focused on knowledge of, experience with, and attitudes towards testing for different genes related to sports proficiency, injury risk, and disease risk. Few AMSSM physicians believe that genetic testing to adapt training (12%) or to choose a sport (2%) is ready for clinical adoption. Most respondents self-reported minimal knowledge about, and limited experience with, genetic testing. The main exception was screening for sickle cell trait (SCT) for which most (84%) reported moderate/significant/expert knowledge and over two-thirds had ordered testing. Although most respondents thought it appropriate to counsel and test for health conditions associated with cardiac and connective tissue disorders in the setting of a positive family history, only a minority had been asked to do so. Five or fewer respondents (2%) had been asked to test for performance-associated variants (Angiotensin Converting Enzyme (ACE) II and Alpha-Actinin 3 (ACTN3)), and five or fewer (2%) would recommend changes based on the results. Our study provides a baseline of current US sports medicine physicians’ minimal experiences with, and knowledge of, genetic testing. The findings of our study indicate that sports medicine physicians require further genetics education as it relates to sports and exercise in order to be prepared to competently engage with their patients and to develop sound professional organizational policies.

Sign in / Sign up

Export Citation Format

Share Document